Cardiology just took back-to-back blows to two of its most promising prevention strategies. One drug for lowering lipoprotein(a) and another targeting interleukin-6 both failed in major trials, even as fresh data reaffirms just how much those factors matter.  This begs the question: are these molecules CVD causes or merely biomarkers? Not to be dramatic, but […] The post Novo, Novartis, and How Two Trials Cast Doubt on CVD Biomarkers appeared first on Cardiac Wire .